Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Virpax Pharmaceuticals ( (VRPX) ) is now available.
On January 27, 2025, Virpax Pharmaceuticals entered into a placement agency agreement with Spartan Capital Securities and a securities purchase agreement with investors for a public offering, which closed on January 29, 2025, generating $6 million in gross proceeds. The funds are earmarked for development activities, including a clinical trial for Probudur, and marketing efforts. Additionally, Virpax signed investor relations agreements with IR Agency LLC and Sideways Frequency LLC to enhance its visibility in the financial community, with services extending for an initial term of one month.
More about Virpax Pharmaceuticals
Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company specializing in the development of novel and proprietary drug delivery systems targeting various pain indications. The company is focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders to enhance patients’ quality of life.
YTD Price Performance: -12.70%
Average Trading Volume: 3,915,390
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $4.39M
For detailed information about VRPX stock, go to TipRanks’ Stock Analysis page.
